Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company, announced Wednesday positive 16-week data from Part B of the Phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe AD.
The trial met all its primary and secondary endpoints with high statistical significance including 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted).
Based on these dose optimization results and subject to regulatory interactions, Apogee plans to move forward with the mid-dose, which achieved the best clinical activity of the three doses tested and was well-tolerated, in its Phase 3 trials in the second half of 2026.
The company also announced a $1.3 billion Strategic financing collaboration with Blackstone Life Sciences that is expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE.
In Wednesday's pre-market trading, TGT is trading on the NYSE at $53.76, up $2.52 or 4.93 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.